Market opportunities for mRNA synthesis raw materials lie in the growing demand for high-purity materials driven by mRNA therapeutics. Key drivers include advancements in mRNA technology, regulatory ...

Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that ...